Bronchogen vs Adipotide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
BronchogenFat Loss & Metabolic
Adipotide- Summary
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- Half-Life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Estimated 2-4 hours
- Admin Route
- SubQ, Oral
- Subcutaneous, Intravenous (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for humans; primate studies used 0.1-1 mg/kg
- Frequency
- Daily for 10–30 days
- Daily for 4 weeks (research protocol)
- Key Benefits
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Side Effects
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Stacks With
- —
- —